ACR 2017

This post-hoc analysis showed that ongoing sarilumab treatment on the MOBILITY and TARGET studies resulted in achievement of remission or low disease activity increased through week 24 in patients with rheumatoid arthritis (RA) and inadequate response to methotrexate and inadequate response to, or intolerance of, tumor necrosis factor inhibitors. Read More ›

Highly sensitive cardiac troponin may provide prognostic information on long-term cardiovascular (CV) event risk assessment in patients with rheumatoid arthritis (RA) without prior diagnosis of CV disease. Read More ›

Post-hoc pooled analyses of the MOBILITY and TARGET trials showed that sarilumab plus disease-modifying antirheumatic drug (DMARD) treatment in diabetic patients with rheumatoid arthritis (RA) led to reductions in glycosylated hemoglobin (HbA1c) and lowered fasting glucose levels; reductions in HbA1c were also achieved by nondiabetic patients with RA. Read More ›

Results of the randomized, placebo-controlled, phase 3 SELECT-NEXT study showed that upadacitinib, a selective JAK-1 inhibitor, at 15 mg and 30 mg once daily, was efficacious in patients with rheumatoid arthritis (RA) who had inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs), with a safety and tolerability profile that was consistent with that previously reported. Read More ›

In this long-term efficacy and safety analysis of the global phase 3 SIRROUND-D trial, improvements in signs and symptoms of rheumatoid arthritis (RA) and health-related physical and emotional well-being were maintained with sirukumab treatment in patients with active RA despite disease-modifying antirheumatic drugs (DMARDs). Read More ›

In this post-hoc analysis of the AMPLE trial, subcutaneous (SC) abatacept treatment was associated with lower cost per responder compared with SC adalimumab in patients with seropositive, erosive early rheumatoid arthritis (RA). Read More ›

This analysis showed that patients with active, moderate-to-severe rheumatoid arthritis (RA) treated with sarilumab plus methotrexate (MTX) achieved longer duration of response versus those treated with placebo plus MTX, regardless of the definition of response used. Read More ›

The findings of the current study suggest that patients with rheumatoid arthritis (RA) who achieve low disease activity with subcutaneous tocilizumab plus methotrexate (MTX) may potentially discontinue MTX and maintain disease control with tocilizumab monotherapy. Read More ›

The findings of this study showed that patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) reported clinically meaningful improvements in patient-reported outcomes (PROs) with all 3 treatment regimens (tofacitinib monotherapy, tofacitinib plus MTX, and adalimumab plus MTX). PROs were comparable between tofacitinib plus MTX and adalimumab plus MTX therapies, with combination therapy numerically higher than tofacitinib monotherapy. Read More ›

In the open-label extension phase of the phase 3 MONARCH trial, patients switching from monotherapy with adalimumab 40 mg to open-label monotherapy with sarilumab 200 mg every 2 weeks demonstrated improvements in rheumatoid arthritis (RA) signs and symptoms and physical function that were numerically similar to patients who were initially randomized to sarilumab 200 mg every 2 weeks. Read More ›

Page 2 of 2